Additional file 2. Structure of the aberrant proviruses isolated from cells treated with suboptimal concentrations of EVG (Table S1); from cells infected with viruses harboring RAL resistant mutations and treated with suboptimal doses of RAL (Tables S2âS4). The inhibitory concentrations of EVG or RAL used to treat the cells are indicated. The aberrations in the viral LTRs and in the integrated host chromosome(s) are indicated. U-LTR: the LTR adjacent to the primer binding site; D-LTR: the LTR adjacent to the polypurine tract
(a)<p>Mutations associated with INIs resistance in HIV-1.</p>(b)<p>Mutations of unknown impact on RA...
Additional file 3: Fig. S4. Spontaneous gp120 shedding from cell surface. The susceptibility of gp41...
Additional file 1. Two sets of supplementary tables are included for Figs. 2, 4, 5, 6, 8, 9, and 10....
Additional file 1: Figure S1. Structure of DNAs used to generate the HIV-1 vectors. At the top is a ...
Integrase inhibitors are emerging anti-human immunodeficiency virus (HIV) drugs, and multiple retrov...
Additional file 10: Figure S9. Proviral integration in the vicinity of Vpr-induced DSB sites. Target...
<p>Panels A and C show the EC<sub>50</sub> values for wild-type (WT) HIV-2 ROD9 and each of 13 site-...
Additional file 1: Fig. S1. Coexpression of HERV-K GagPro reduces HIV-1 release efficiency and infec...
Raltegravir is the first integrase strand-transfer inhibitor (INSTI) approved for use in highly acti...
Additional file 7: Figure S7. Quantitative PCR of HIV-1 2-LTR, integrated provirus and cDNA per cell...
More than 200 mutations are associated with antiretroviral resistance to drugs belonging to six lice...
Additional file 1: Table S1âS4. The IC50 values (nM) of RPV and the RPV analogs were determined ag...
<p>3D structure of HIV-2 integrase, modelled from the Prototype Foamy Virus (PDB ID 3L2V), shown in ...
<div><p>Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside rev...
Additional file 1. Supplementary methods. Chemical synthesis process of MUT-A,HTRF®-based IN-LEDGF i...
(a)<p>Mutations associated with INIs resistance in HIV-1.</p>(b)<p>Mutations of unknown impact on RA...
Additional file 3: Fig. S4. Spontaneous gp120 shedding from cell surface. The susceptibility of gp41...
Additional file 1. Two sets of supplementary tables are included for Figs. 2, 4, 5, 6, 8, 9, and 10....
Additional file 1: Figure S1. Structure of DNAs used to generate the HIV-1 vectors. At the top is a ...
Integrase inhibitors are emerging anti-human immunodeficiency virus (HIV) drugs, and multiple retrov...
Additional file 10: Figure S9. Proviral integration in the vicinity of Vpr-induced DSB sites. Target...
<p>Panels A and C show the EC<sub>50</sub> values for wild-type (WT) HIV-2 ROD9 and each of 13 site-...
Additional file 1: Fig. S1. Coexpression of HERV-K GagPro reduces HIV-1 release efficiency and infec...
Raltegravir is the first integrase strand-transfer inhibitor (INSTI) approved for use in highly acti...
Additional file 7: Figure S7. Quantitative PCR of HIV-1 2-LTR, integrated provirus and cDNA per cell...
More than 200 mutations are associated with antiretroviral resistance to drugs belonging to six lice...
Additional file 1: Table S1âS4. The IC50 values (nM) of RPV and the RPV analogs were determined ag...
<p>3D structure of HIV-2 integrase, modelled from the Prototype Foamy Virus (PDB ID 3L2V), shown in ...
<div><p>Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside rev...
Additional file 1. Supplementary methods. Chemical synthesis process of MUT-A,HTRF®-based IN-LEDGF i...
(a)<p>Mutations associated with INIs resistance in HIV-1.</p>(b)<p>Mutations of unknown impact on RA...
Additional file 3: Fig. S4. Spontaneous gp120 shedding from cell surface. The susceptibility of gp41...
Additional file 1. Two sets of supplementary tables are included for Figs. 2, 4, 5, 6, 8, 9, and 10....